New drug brensocatib now available for bronchiectasis patients who completed key trial
NCT ID NCT05344508
First seen Nov 05, 2025 · Last updated May 23, 2026 · Updated 28 times
Summary
This program provides early access to brensocatib for people with non-cystic fibrosis bronchiectasis who finished the ASPEN study. The drug aims to control lung symptoms and reduce flare-ups. Participants must have taken brensocatib before and not had serious side effects related to it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-CYSTIC FIBROSIS BRONCHIECTASIS are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.